CoChat

Amyloid-β oligomers regulate the properties of human neural stem cells through GSK-3β signaling

Open access
Lee, Il-Shin, Jung, Kwangsoo, Kim, Il-Sun, Park, Kook In · 2013 · Experimental & Molecular Medicine
Cited by 62

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common cause of age-related dementia. The neuropathological hallmarks of AD include extracellular deposition of amyloid-β peptides and neurofibrillary tangles that lead to intracellular hyperphosphorylated tau in the brain. Soluble amyloid-β oligomers are the primary pathogenic factor leading to cognitive impairment in AD. Neural stem cells (NSCs) are able to self-renew and give rise to multiple neural cell lineages in both developing and adult central nervous systems. To explore the relationship between AD-related pathology and the behaviors of NSCs that enable neuroregeneration, a number of studies have used animal and in vitro models to investigate the role of amyloid-β on NSCs derived from various brain regions at different developmental stages. However, the Aβ effects on NSCs remain poorly understood because of conflicting results. To investigate the effects of amyloid-β oligomers on human NSCs, we established amyloid precursor protein Swedish mutant-expressing cells and identified cell-derived amyloid-β oligomers in the culture media. Human NSCs were isolated from an aborted fetal telencephalon at 13 weeks of gestation and expanded in culture as neurospheres. Human NSCs exposure to cell-derived amyloid-β oligomers decreased dividing potential resulting from senescence through telomere attrition, impaired neurogenesis and promoted gliogenesis, and attenuated mobility. These amyloid-β oligomers modulated the proliferation, differentiation and migration patterns of human NSCs via a glycogen synthase kinase-3β-mediated signaling pathway. These findings contribute to the development of human NSC-based therapy for AD by elucidating the effects of Aβ oligomers on human NSCs. Aggregates of the protein amyloid-β - responsible for Alzheimer's disease - appear to modulate the properties of neural stem cells (NSCs), self-renewing precursors of different types of brain cell. The finding should be considered when designing cell therapies for the neurodegenerative disorder. Kook In Park and colleagues from the Yonsei University College of Medicine in Seoul, South Korea, treated human NSCs with clumps of amyloid-β protein similar to those commonly found in the brains of Alzheimer's patients. The researchers observed that amyloid-β exposure reduced the dividing potential of the stem cells as well as restricted their proliferation, differentiation and migration abilities. These effects were mediated in part by glycogen synthase kinase-3β (GSK-3β), an enzyme activated by amyloid-β. The amyloid-β assemblies also accelerated the shortening of chromosomal caps (called telomeres) in the NSCs, leading to premature cell aging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2013.125

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 23 references

Cited by

Metadata

Authors
Lee, I.-S., Jung, K., Kim, I.-S., & Park, K. I.
Venue
Experimental & Molecular Medicine
Published
2013-11-15
Volume
45
Issue
11
Pages
e60-e60
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W2018496107
Cited by
62
References
23
FWCI
2.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.